The response of circulating effector CD4 T cells to type I interferons (IFN-I) correlates with the overall survival of patients with cancer receiving immune checkpoint inhibition. IFN-I responsiveness is already epigenetically encoded before treatment initiation, highlighting a deterministic, clinically relevant feature that can predict therapeutic efficacy.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Gellrich, F. F. et al. Anti-PD-1 and novel combinations in the treatment of melanoma–an update. J. Clin. Med. 9, 223 (2020). This paper reviews different ICI combinations and their response rates across many different clinical trials in patients with metastatic melanoma.
Boukhaled, G. M. et al. Opposing roles of type I interferons in cancer immunity. Annu. Rev. Pathol. 16, 167–198 (2021). A comprehensive review of the diverse roles of IFN-I in cancer cells and tumor immunology.
Benci, J. L. et al. Opposing functions of interferon coordinate adaptive and innate immune response to cancer immune checkpoint blockade. Cell 178, 933–948 (2019). A paper reporting that IFNs exert distinct and opposing functions on tumor and immune cells, limiting tumor cell death.
Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Investig. 127, 2930–2940 (2017). An Article that shows that higher IFN-II response in the tumor positively correlates with patient outcome.
Abdel-Hakeem, M. S. et al. Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigen stimulation. Nat. Immunol. 22, 1008–1019 (2021). This study demonstrates that exhausted T cells with epigenetic scars fail to develop into functional memory T cells.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Boukhaled, G. M. et al. Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy. Nat. Immunol. https://doi.org/10.1038/s41590-022-01262-7 (2022).
About this article
Cite this article
Reactivity to type I interferon is key to predict cancer immunotherapy response. Nat Immunol 23, 1146–1147 (2022). https://doi.org/10.1038/s41590-022-01278-z